Men with low-risk prostate cancer have good mortality prospects even when they experience early biochemical recurrence following radical prostatectomy, according to the results of an Australian study.
Disitamab vedotin shows promise in HER2+ metastatic urothelial carcinoma
"In these studies, we were pleased to find that disitamab vedotin has consistent efficacy and manageable safety in patients with chemotherapy-refractory mUC," says Jun Guo, MD.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Actress Holly Robinson Peete takes part in OAB campaign
"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Studies explore resistance to hormone therapy in prostate cancer
“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.
Midlantic Urology’s Dr. Dean Laganosky is first US urologist to implant FDA-approved balloon spacer for prostate cancer
“This next-generation rectal spacing option is the first of its kind...and has the potential to provide an enhanced degree of protection from the genitourinary and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.
2 Clarke Drive Cranbury, NJ 08512